Authors
Latest:
Dr. Janice M. Mehnert on Immunotherapy vs BRAF/MEK Inhibitors in the Adjuvant Setting for MelanomaCancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.
Latest:
Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast CancerCancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.
Latest:
Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid TumorsCancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Latest:
Fergus Couch, PhD, on the CARRIERS Studies in Breast CancerFergus Couch, PhD, from the Mayo Clinic, discusses with CancerNetwork about the new research with the CARRIERS study for African American patients with breast cancer.
Latest:
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?This review summarizes the major clinical trials that led to the approval of antiangiogenic drugs for ovarian cancer and gives a brief view into novel combinations of bevacizumab with other targeted therapies in an attempt to enhance the efficacy of bevacizumab.
Latest:
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?This review summarizes the major clinical trials that led to the approval of antiangiogenic drugs for ovarian cancer and gives a brief view into novel combinations of bevacizumab with other targeted therapies in an attempt to enhance the efficacy of bevacizumab.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Evolution of Lung Cancer Screening ManagementThroughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.
Latest:
Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid LeukemiaThis article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.
Latest:
Multiple Primary Tumors Over a LifetimeThe risk of multiple primary cancers is increasing due to increasing numbers of survivors, long-term side effects of chemotherapy and/or radiation therapy, increased diagnostic sensitivity, and persisting effects of genetic and behavioral risk factors.
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular CarcinomaA thought-provoking installment of Clinical Quandaries is presented by Alejandro Gabutti, MD; and Tommaso Cascella, MD, of a 36-year-old patient with hepatitis C virus-related cirrhosis and a subsequent diagnosis of hepatocellular carcinoma.
Latest:
Diffuse Hepatic Infiltration by Metastatic MelanomaMelanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Latest:
Dr. Kelly Hunt on the Role of Surgery in Metastatic Breast CancerCancer Network spoke with Kelly Hunt, MD, professor and chair of the department of breast surgical oncology at the MD Anderson Cancer Center in Houston, about the role of surgery in metastatic breast cancer.
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Management of Steroid-Refractory Immune-Related Adverse EventsThe increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Latest:
Management of Steroid-Refractory Immune-Related Adverse EventsThe increasing utilization of these immune checkpoint inhibitors has presented new of immune-related adverse events that have proven to be extremely challenging to manage.
Latest:
HPV and the Immune System in Head and Neck Cancers: Therapeutic ConsiderationsA review of the role of immune therapy in HPV-associated head and neck squamous cell carcinoma, along with the evidence and perspective behind differing therapeutic considerations.
Latest:
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the BrainBrain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
Latest:
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the BrainBrain metastasis is common in breast cancer and often has a poor prognosis, but there are several ways to manage brain metastasis in breast cancer including focal therapies as well as systemic options for specific populations, including emerging and novel therapies.
Latest:
Pediatric Acute Lymphoblastic LeukemiaONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.
Latest:
Monitoring for Thyroid Cancer RecurrenceAlan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer.
Latest:
Erdafitinib in the Treatment of Metastatic Urothelial CarcinomaFrancisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.
Latest:
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Latest:
What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?
Latest:
Black, Elderly Patients Less Likely to Receive Treatment for Lung CancerAbout a fifth of patients with lung cancer in the United States receive no treatment at all, while approximately 6 in 10 receive the minimal treatments recommended by the National Comprehensive Cancer Network.
Latest:
2019 World Conference Of Lung Cancer Round-UpFive notable abstracts from the 2019 World Conference on Lung Cancer (WCLC).
Latest:
67-year-old Male with Prostatic Stromal Tumor of Uncertain Malignant PotentialSTUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
